We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+39.07%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.38B
AUM Growth
+$198M
Cap. Flow
-$130M
Cap. Flow %
-5.45%
Top 10 Hldgs %
45.26%
Holding
80
New
15
Increased
16
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$84.7M
2
INSM icon
Insmed
INSM
+$82.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$61.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$50.7M
5
AUTL
Autolus Therapeutics
AUTL
+$37.9M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$98.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$80M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
4
KURA icon
Kura Oncology
KURA
+$43.5M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
1
Immunovant
IMVT
$7.8B
$172M 7.24%
9,710,000
-150,246
-2% -$1.89M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$169M 7.08%
7,878,119
+878,119
+13% +$18.7M
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$16.1B
$139M 5.84%
873,553
+12,553
+1% +$1.84M
TVTX icon
4
Travere Therapeutics
TVTX
$5.12B
$96.4M 4.05%
4,582,000
+582,000
+15% +$12.3M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.5B
$85.5M 3.59%
700,000
-100,000
-13% -$11.6M
INSM icon
6
Insmed
INSM
$22.5B
$85.2M 3.58%
+4,264,292
New +$82.4M
BCYC
7
Bicycle Therapeutics
BCYC
$269M
$83.4M 3.5%
2,819,045
-80,955
-3% -$2.17M
VRNA
8
DELISTED
Verona Pharma
VRNA
$83.3M 3.5%
3,187,415
+358,321
+13% +$4.77M
BIIB icon
9
Biogen
BIIB
$31.1B
$83.1M 3.49%
+300,000
New +$84.7M
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$80.9M 3.4%
3,109,886
+740,676
+31% +$18.2M
KDNY
11
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$78.6M 3.3%
3,000,000
– –
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.64B
$68.4M 2.87%
+528,244
New +$61.2M
AGEN
13
Agenus
AGEN
$280M
$64.8M 2.72%
1,375,650
+34,391
+3% +$1.75M
FDMT icon
14
4D Molecular Therapeutics
FDMT
$495M
$59M 2.48%
2,656,901
-539,741
-17% -$8.34M
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$56.9M 2.39%
500,000
-962,800
-66% -$80M
HZNP
16
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$56.9M 2.39%
+500,000
New +$41.5M
DICE
17
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$54.1M 2.27%
1,734,143
+734,143
+73% +$23.9M
VRDN icon
18
Viridian Therapeutics
VRDN
$2.14B
$51.7M 2.17%
1,771,154
-199,136
-10% -$4.59M
ETNB
19
DELISTED
89bio
ETNB
$49M 2.06%
3,850,000
+1,214,000
+46% +$10.9M
BEAM icon
20
Beam Therapeutics
BEAM
$2.68B
$45.6M 1.92%
1,166,473
+166,473
+17% +$7.46M
IONS icon
21
Ionis Pharmaceuticals
IONS
$9.03B
$45.5M 1.91%
+1,205,773
New +$50.7M
ALLK
22
DELISTED
Allakos
ALLK
$41.3M 1.73%
4,899,179
+380,604
+8% +$2.64M
RPTX
23
DELISTED
Repare Therapeutics
RPTX
$40.1M 1.68%
2,727,606
-400,061
-13% -$5.98M
ALBO
24
DELISTED
Albireo Pharma Inc
ALBO
$36.8M 1.55%
1,704,000
+593,376
+53% +$12.5M
PLRX icon
25
Pliant Therapeutics
PLRX
$65.6M
$33.5M 1.41%
1,732,946
+333,202
+24% +$6.97M
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Deep Track Capital held 80 positions worth $2.38B, up 9.1% from $2.18B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Deep Track Capital withdrew a net $130M in Q4 2022, closing 20 positions and reducing 23 holdings. Its most notable exit was NovoCure, an estimated $98.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Biogen worth $83.1M.

  • Deep Track Capital's largest Q4 2022 buy was Biogen: 300,000 shares worth $83.1M.
  • Deep Track Capital added most to DICE Therapeutics, Inc. Common Stock in Q4 2022, an estimated $23.9M increase.
  • Deep Track Capital's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $80M.
  • Deep Track Capital fully exited NovoCure in Q4 2022, selling an estimated $98.3M.
  • Deep Track Capital's ten largest holdings make up 45% of its $2.38B portfolio in Q4 2022.
  • Deep Track Capital opened 15 new positions and closed 20 in Q4 2022.
  • Deep Track Capital's portfolio value rose 9.1% quarter-over-quarter to $2.38B.

Based on Deep Track Capital's 13F filing for Q4 2022, filed 14 Feb 2023.